| Literature DB >> 29898269 |
Adrian M J Pokorny1,2,3, Venessa T Chin1,4, Adnan M Nagrial5,6, Desmond Yip7,8, Lorraine A Chantrill1,4.
Abstract
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.Entities:
Keywords: adenocarcinoma; cancer genomics; clinical trials; cytotoxic chemotherapy; metastatic; pancreatic cancer
Mesh：
Substances：
Year: 2018 PMID： 29898269 DOI： 10.1111/imj.13810
Source DB: PubMed Journal: Intern Med J ISSN： 1444-0903 Impact factor: 2.048